Earnings Call · Q1 FY2024·2024-05-08

Q1 24EPS +13.27%·Rev n/aQ4 23EPS -3.09%·Rev n/aQ3 23EPS +8.75%·Rev n/aQ2 23EPS +14.67%·Rev n/a⚠ consensus missing

Syndax Pharmaceuticals Inc SNDX

Sharon Klahre — Head of Investor Relations

Michael Metzger — Chief Executive Officer

Neil Gallagher — President and Head of R&D

Steven Closter — Chief Commercial Officer

Keith Goldan — Chief Financial Officer

−3.5%1d on move date−3.5% vs SPY3d−6.2%5d−6.6%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SNDX calls or request research access.

More SNDX calls Browse calls Request research access